NIH-funded research NIH-funded research

Developing a new treatment to improve muscle strength in older adults after hip fractures

Official title: Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture

Funded at Ridgeline Therapeutics, LLC · NIH-10696182 · Data updated 2026-11-12

This study is testing a new treatment that helps older adults, especially those who have had hip fractures, regain muscle strength and improve their recovery after surgery by boosting their muscle repair cells.

More Aging research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionRidgeline Therapeutics, LLC
NIH-funded
Lab location1 site (Houston, UNITED STATES)
Project startSeptember 30, 2021
Project endAugust 31, 2025
Funding year2023
Award (this year)$1,242,959
NIH project number5U44AG074107-03
Project IDNIH-10696182 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are older adults aged 60 and above who have experienced a hip fracture and are facing challenges in muscle recovery.

Less likely to help

Patients who are younger than 60 or those who have not suffered a hip fracture may not benefit from this research.

What this research studies

This research focuses on addressing the decline in muscle mass and strength that occurs with aging, particularly in older adults who have suffered hip fractures. The approach involves developing a novel small molecule treatment that targets and rejuvenates aging muscle stem cells, which are crucial for muscle repair and regeneration. By reactivating these cells, the research aims to enhance muscle strength and functional recovery post-surgery, ultimately improving the quality of life for elderly patients. The study will evaluate the effectiveness of this treatment in restoring muscle function and reducing the risk of further injuries.

Why it matters

Potential benefit: If successful, this research could significantly improve recovery outcomes and quality of life for older adults recovering from hip fractures.

How similar studies have gone: While there have been attempts to improve muscle strength in the elderly, this specific approach using NNMT inhibitors is novel and has not been tested in this context before.

Where this research is happening

  • Ridgeline Therapeutics, LLC
    Houston, United States
    Active

Researchers

  • Principal investigator: Neelakantan, Harshini — Ridgeline Therapeutics, LLC
  • Study coordinator: Neelakantan, Harshini

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.